Parker Institute for Cancer Immunotherapy

PICI is an active research institute, not a passive grantmaker. It directly coordinates collaborative projects among its network of partner cancer centers, sharing data and infrastructure to run joint clinical trials. The model is designed to remove institutional barriers and speed up the translation of scientific discoveries into patient treatments.

No. PICI does not provide direct patient care. It collaborates with top-tier cancer research centers that do treat patients, facilitating clinical trials and research studies across its institutional network.

The network includes several of the most prominent cancer research institutions in the United States. Confirmed members include Stanford Medicine and Memorial Sloan Kettering Cancer Center, alongside other unlisted centers that collectively form the collaborative backbone of the institute.

PICI is structured as an operating research institute. It does not manage a portfolio of external investments or function as a family office. Its resources are directed entirely toward its internal scientific mission — coordinating network-based cancer immunotherapy research.

The institute’s central operations are based in San Francisco, but it maintains a significant multi-hub presence. It lists additional locations in Boston, Santa Barbara, Zurich, and Basel, enabling it to coordinate transatlantic research efforts with European partners.